2 weeks Ago By ABMN Staff
Rhumbline Advisers purchased a new position in shares of Elevation Oncology, Inc. ( NASDAQ:ELEV – Free Report ) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 64,910 shares of the company’s stock, valued at approximately $175,000.
A number of other large investors have also bought and sold shares of ELEV. SG Americas Securities LLC purchased a new stake in shares of Elevation Oncology during the first quarter valued at approximately $63,000. Bank of New York Mellon Corp purchased a new position in shares of Elevation Oncology in the second quarter worth $415,000.
Affinity Asset Advisors LLC bought a new stake in Elevation Oncology during the 1st quarter valued at $6,509,000. Artal Group S.A.
purchased a new stake in Elevation Oncology during the 1st quarter valued at $7,762,000. Finally, Vanguard Group Inc. grew its holdings in Elevation Oncology by 30.
8% in the 1st quarter. Vanguard Group Inc. now owns 1,532,045 shares of the company’s stock worth $7,859,000 after acquiring an additional 360,799 shares during the last quarter.
83.70% of the stock is owned by hedge funds and other institutional investors. Analyst Upgrades and Downgrades Several brokerages have recently commented on ELEV.
JMP Securities reaffirmed a “market outperform” rating and set a $7.00 price objective on shares of Elevation Oncology in a research note on Monday, July 15th. Wedbush reaffirmed an “outperform” rating and set a $8.
00 price target on shares of Elevation Oncology in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Elevation Oncology in a report on Wednesday, August 7th.
Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $7.80. Elevation Oncology Price Performance ELEV stock opened at $0.
59 on Monday. The firm has a 50-day moving average of $1.12 and a 200 day moving average of $2.
79. The company has a debt-to-equity ratio of 0.38, a current ratio of 41.
10 and a quick ratio of 41.10. The company has a market cap of $32.
24 million, a P/E ratio of -0.57 and a beta of 1.26.
Elevation Oncology, Inc. has a 1 year low of $0.36 and a 1 year high of $5.
83. Elevation Oncology ( NASDAQ:ELEV – Get Free Report ) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.
18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05.
On average, sell-side analysts forecast that Elevation Oncology, Inc. will post -0.82 EPS for the current year.
Elevation Oncology Profile ( Free Report ) Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Recommended Stories Want to see what other hedge funds are holding ELEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevation Oncology, Inc. ( NASDAQ:ELEV – Free Report ).
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter ..
